Homologous Stem Cell Injection

What Happens Before Injection?

Although the homologous injection procedure is not available yet, it will require patients to come in for an initial visit during which a blood sample must be collected. This blood sample is then used to determine the histocompatibility between the patient and the donor stem cells obtained from cord blood.

The hundreds (if not thousands) of steps needed to be completed before the stem cell injection explain why stem cell therapies are regulated by the FDA, and why they are so complicated to enact. There are lots of procedures that need to completed with safety and sterility in mind to ensure that the injection helps the patient. Altogen Labs takes every step seriously, and makes sure that all proper documentation and registration is complete before any step is completed.

What Happens During Injection?

The injection procedure is relatively straightforward – the stem cells are injected into the bloodstream near damaged tissue. This injection does not require anaesthesia (only a local anaesthetic if necessary), and does not take much time.

A relatively wide needle is used for the injection, as smaller needles may crush the stem cells, rendering them useless. During the injection visit, pre-frozen stem cell samples are thawed and mixed with special compounds to make sure that the stem cells remain active after they are injected into a patient. This thawing procedure is quick, and immediately after thawing the stem cells are injected.

What Happens After Injection?

As with the autologous injection, side effects must be monitored, particularly in context of the injection site. However, the added benefit of the homologous therapy (when it becomes available) is the lack of a bone marrow aspiration procedure, which reduces the pain of the procedure considerably.

Unlike an autologous injection, the homologous injection uses the stem cells of another individual. Though screening measures are in place, there is always the risk of incompatibility between the donor and the patient. Regular screenings are necessary to ensure that the injection procedure did not lead to any transferable diseases or conditions. As we develop our homologous injection procedure, we are making sure that all relevant measures are in place to reduce such a risk. Nonetheless, having the injection site monitored up to a year after the injection is necessary in case of the development of a malignant condition such as a tumor.